Navigation Links
Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’


Dr Jonathan Brotchie

Dr Jonathan Brotchie is Senior Scientist at the Toronto Western Hospital, part of the University Health Network (UHN) in Toronto, Canada. He is also the Founder and Chief Executive Officer of Atuka Ltd., a contract research and consultancy services company for the development of novel therapeutics and diagnostics for Parkinson's disease. Jonathan is a renowned scientist in the field of Parkinson's disease and, at UHN runs one of the world's premier research laboratories for the identification of novel treatments, diagnostics and cures for Parkinson's and related disorders. In the last decade, he has published many influential scientific papers in the field of Parkinson's disease and related disorders. His research has been particularly associated with pioneering the concept of non-dopaminergic treatments for Parkinson's disease.

Jonathan is also Scientific Director of the Cure Parkinson's Trust, a charity supporting research aimed at delivering better treatments and cures for PD.


The Cure Parkinson's Trust

The Cure Parkinson's Trust supported by Movers & Shakers was co-founded by four individuals with Parkinson's who are determined to do everything in their power to help find a cure for this debilitating neurological disease. They are former Lord Mayor of London, Sir Richard Nichols, David Jones CBE, former chairman of Next Plc, Michael Hughes and Tom Isaacs.


Parkinson's disease can affect anyone at any time. It does not discriminate by age, sex or nationality. One in every 500 people, contracts Parkinson's, with one in every 20 of those diagnosed each year being under the age of 40 years. A cure for Parkinson's disease is within reach.


The Cure Parkinson's Trust has been funding a variety of research projects globally. For further details see: www.cureparkinsons.org.uk


Mo Noonan Mana
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:7/22/2008)...SOUTH SAN FRANCISCO, Calif., July 22 /PRNewswire/ ...t it has completed patient enrollment,in its Phase...bility and,ammonia scavenging effects of HPN-100 (...henylbutyrate) in patients with urea cycle disorde...esults in the fourth quarter,of this year., (Logo...
(Date:7/22/2008)... Developed and Validated by Columbia University Me...Proprietary MicroRNA Technology, The Test Differ... Lung Cancer (NSCLC), Classifying Squamous-Cell C... Percent and Specificity of 90 Percent,This is the...s, Sensitivity as Biomarkers for Accurate...
(Date:7/22/2008)...SOPHIA ANTIPOLIS, France, July 22 /PRNewswire-Firs...nnounced it has successfully completed the,enrollm...olled hypertension,in two clinical pharmacology st...y announced timelines. These trials are designed t..., in comparison to ibuprofen and,naproxen, using t...
(Date:7/22/2008)...Pilot Study Suggests That Ekkyo,s New Approach of ...ally Improve Scar Healing Physiology, MARSEILLES,...nown as,Heatwave Technology) a photomedicine compa...ems for skin scar prevention and reduction, announ...in Lasers in Surgery and Medicine*,reporting the r...
Breaking Medicine Technology:Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 1Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 2Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 3Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 4JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 1JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 2JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 3JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 4ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 1ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 2ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 3Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 1Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 2Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 3
...f.--(BUSINESS WIRE)--Jun 4, 2007 - Researchers at ...luminated the path,taken by human neural stem cell...nd mice, and found that the cells successfully,nav...h group placed miniscule particles of iron inside,...magnetic,resonance imaging. With the ability to mo...
... Affiliated Physicians Participate in ASCO,Proceed...ding cancer,researcher affiliated with the US Onco...ndomized, multicenter phase III trial,that compare...o,regimens of adjuvant therapy for patients with h...iven in an oral presentation by Dr.,David Loesch o...
Other Medicine Technology:Stanford Researchers Track Human Stem Cells Transplanted Into Rat,Brain 2Stanford Researchers Track Human Stem Cells Transplanted Into Rat,Brain 3Stanford Researchers Track Human Stem Cells Transplanted Into Rat,Brain 4New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 2New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 3New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 4New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 5
(Date:7/25/2008)... jobs created in the medical field slowed in June,...d of slowdown: they laid off fewer people in June ... Seattle, WA (PRWEB) July 25, 2008 -- Though the ... in June overall, pharmaceutical companies reporte...to the ears of sales representatives: fewer layoff...
(Date:7/25/2008)... J. Reilly, Joins Aethon Team, PITTSBURGH, July 2...com ), the leading developer of mobile robotics fo... that Robert J. Reilly has,joined the company as S... Reilly, who was most recently Vice President -- G...y Pharmacy Division, brings more than 30,years of ...
(Date:7/25/2008)...se immune system changes , , FRIDAY, Jul...g gastroesophageal reflux disease (GERD) and asthm...enter researchers. , An association between the...since then studies have shown that between 50 perc...nce GERD symptoms. But the actual link between GER...
(Date:7/25/2008)... Association (DIA) and the Food and Drug Administr... (CPI) on the Move: Complexities and Challenges (S...th Transporter Workshop (October 2-3; North Bethes...RWEB) July 25, 2005-- The http://www.diahome.org/...d and Drug Administration (FDA) will host the htt...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3
...enge releases a dose of nicotine and is one of the...uit smoking.// The federal government has announc...nada. The lozenges are to join nicotine patches, g...er the counter. This decision was taken because th...
...re Commission today came down heavily on senior ma...were responsible for the spread of a lethal bug// ...gets above infection control. A couple of outbrea...pital resulted in 33 deaths far more than the 12 o...
...e-up of community health care could cause a change...e been made to merge the roles of community health...t nurses into one community health job. This could...ss Scotland. These were the plans that were outli...
...shington residents have taken ill after eating raw...t of Health has reported. The Health department ha...oid eating raw shellfish. Oysters that are prope...ut raw oysters may be prone to bacteria that is fo...
Other Medicine News:Health News:"Serious Failings" Led To Spread Of Lethal Hospital Bug 2
Packed conveniently in plastic-wrapped racks of 96 tips, Sterilized Diamond- Tips are ready to useno need to autoclave. Sterilized Diamond Tips are irradiated by gamma-rays for more efficient sterili
Designed for applications that demand the utmost in biological purity, individually packed Finntip BioCon tips are endotoxin-free, DNA-free, DNase-free and RNase-free. Finntip BioCon tips are guaran
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting.
Medicine Products: